0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia

E. DONNALL THOMAS, M.D.; REGINALD A. CLIFT, F.I.M.L.S.; ALEXANDER FEFER, M.D.; FREDERICK R. APPELBAUM, M.D.; PATRICK BEATTY, M.D.; WILLIAM I. BENSINGER, M.D.; C. DEAN BUCKNER, M.D.; MARTIN A. CHEEVER, M.D.; H. JOACHIM DEEG, M.D.; KRISTINE DONEY, M.D.; NANCY FLOURNOY, Ph.D.; PHILIP GREENBERG, M.D.; JOHN A. HANSEN, M.D.; PAUL MARTIN, M.D.; ROBERT McGUFFIN, M.D.; ROBERT RAMBERG, B.Sc.; JEAN E. SANDERS, M.D.; JACK SINGER, M.D.; PATRICIA STEWART, M.D.; RAINER STORB, M.D.; KEITH SULLIVAN, M.D.; PAUL L. WEIDEN, M.D.; and ROBERT WITHERSPOON, M.D.
[+] Article and Author Information

▸Requests for reprints should be addressed to E. Donnall Thomas, M.D.; Division of Oncology, Fred Hutchinson Cancer Research Center; 1124 Columbia Street; Seattle, WA 98104.


Seattle, Washington


©1986 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1986;104(2):155-163. doi:10.7326/0003-4819-104-2-155
Text Size: A A A

One hundred ninety-eight patients with chronic myelogenous leukemia received marrow transplants after intensive chemotherapy and total body irradiation. Multivariate analysis showed disease status at time of transplantation to be the most powerful predictor of survival. The probability of long-term survival for allogeneic graft recipients was 49% for 67 patients in the first chronic phase, 58% for 12 in the second chronic phase, 15% for 46 in the accelerated phase, and 14% for 42 in the blastic phase. The major cause of death was interstitial pneumonia for patients in the chronic phase, and relapse for those in the blastic or accelerated phases. Factors favoring survival were early transplantation, age less than 30 years, and absence of severe graft-versus-host disease. Splenectomy or spleen size did not influence survival. For recipients of syngeneic grafts survival probability was 87% for 16 patients in the chronic phase, 27% for 7 in the accelerated phase, and 12% for 8 in the blastic phase. Of the 198 patients, 71 are alive without Philadelphia chromosomes 1 to 9 years after receiving their graft. All but 4 long-term disease-free survivors have Karnofsky performance scores of 80% or better.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)